Business Description
CareDx Inc
NAICS : 325413
SIC : 8071
ISIN : US14167L1035
Share Class Description:
FRA:1K9: Ordinary SharesDescription
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.88 | |||||
| Equity-to-Asset | 0.56 | |||||
| Debt-to-Equity | 0.13 | |||||
| Debt-to-EBITDA | -0.4 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -0.97 | |||||
| Beneish M-Score | -3.45 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8 | |||||
| 3-Year EBITDA Growth Rate | -107.8 | |||||
| 3-Year EPS without NRI Growth Rate | -78.1 | |||||
| 3-Year Book Growth Rate | -3.3 | |||||
| Future 3-5Y Total Revenue Growth Rate | 2.84 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29.03 | |||||
| 9-Day RSI | 32.05 | |||||
| 14-Day RSI | 35.67 | |||||
| 6-1 Month Momentum % | 72 | |||||
| 12-1 Month Momentum % | 17.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.02 | |||||
| Quick Ratio | 3.77 | |||||
| Cash Ratio | 3.02 | |||||
| Days Inventory | 66.95 | |||||
| Days Sales Outstanding | 72.92 | |||||
| Days Payable | 39.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.4 | |||||
| Shareholder Yield % | 5.15 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 63.61 | |||||
| Operating Margin % | -37.37 | |||||
| Net Margin % | -67.88 | |||||
| FCF Margin % | -9.86 | |||||
| ROE % | -49.77 | |||||
| ROA % | -37.25 | |||||
| ROIC % | -53.83 | |||||
| ROC (Joel Greenblatt) % | -128.21 | |||||
| ROCE % | -24.01 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.53 | |||||
| PB Ratio | 1.57 | |||||
| Price-to-Tangible-Book | 2.26 | |||||
| EV-to-EBIT | -1.81 | |||||
| EV-to-EBITDA | -2.24 | |||||
| EV-to-Revenue | 0.68 | |||||
| EV-to-Forward-Revenue | 0.72 | |||||
| EV-to-FCF | -7.67 | |||||
| Price-to-Net-Current-Asset-Value | 3.65 | |||||
| Price-to-Net-Cash | 13.36 | |||||
| Earnings Yield (Greenblatt) % | -55.14 | |||||
| FCF Yield % | -7.06 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers